Related references
Note: Only part of the references are listed.Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaf tor/ivacaf tor compared to males
B. L. Aalbers et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development network
Kelsie Pearson et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
Pierre-Regis Burgel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy
Dave P. Nichols et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study
Edith T. Zemanick et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry
Christopher R. Kawala et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation *
J. S. Guimbellot et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era
Raksha Jain et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes
Peter J. Barry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis The SIMPLIFY Clinical Trial Study Design
Nicole Mayer-Hamblett et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial
Scott D. Sagel et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2021)
Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
Kate M. O'Shea et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries
Nataliya Volkova et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
The future of cystic fibrosis care: a global perspective
Scott C. Bell et al.
LANCET RESPIRATORY MEDICINE (2020)
Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy
Alex H. Gifford et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males
Katharine E. Secunda et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications
Marcus A. Mall et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
Building global development strategies for cf therapeutics during a transitional cftr modulator era
N. Mayer-Hamblett et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Perspective: A test for those left behind
Steven M. Rowe
NATURE (2020)
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)
Margaret Rosenfeld et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Standardization of Spirometry 2019 Update An Official American Thoracic Society and European Respiratory Society Technical Statement
Brian L. Graham et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor A Cohort Study from the Cystic Fibrosis Registry of Ireland
Laura Kirwan et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2019)
Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial
Felix Ratjen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Retrospective observational study of French patients with cystic fibrosis and a G1y551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting
Dominique Hubert et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Physiological and pharmacological characterization of the N1303K mutant CFTR
Samantha DeStefano et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Ivacaftor-induced sweat chloride reductions correlate with increases in airway surface liquid pH in cystic fibrosis
Mahmoud H. Abou Alaiwa et al.
JCI INSIGHT (2018)
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
Venkateshwar Mutyam et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor
Meredith C. Fidler et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation
Philip M. Farrell et al.
JOURNAL OF PEDIATRICS (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
Katherine B. Hisert et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data
Gregory S. Sawicki et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor
Sonya L. Heltshe et al.
CLINICAL INFECTIOUS DISEASES (2015)
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551D-mediated Cystic Fibrosis
Steven M. Rowe et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation
Jane C. Davies et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Understanding the Relationship Between Sweat Chloride and Lung Function in Cystic Fibrosis
Sonya L. Heltshe et al.
CHEST (2013)
Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial
Jane Davies et al.
LANCET RESPIRATORY MEDICINE (2013)
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations
Philip H. Quanjer et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection
Alexandra L. Quittner et al.
CHEST (2009)
Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: Results of a systematic review
Virginia A. Stallings et al.
JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION (2008)
Restoration of W1282X CFTR activity by enhanced expression
Steven M. Rowe et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
Share Paper
